发明公开
EP2566855A1 2,5,6,7-TETRAHYDRO-[1,4]OXAZEPIN-3-YLAMINE OR 2,3,6,7-TETRAHYDRO-[1,4]OXAZEPIN-5-YLAMINE COMPOUNDS
有权
-2,5,6,7-四氢 - [1,4]氧氮杂-3-基胺OR -2,3,6,7-四氢 - [1,4]氧氮杂-5-基胺化合物
- 专利标题： 2,5,6,7-TETRAHYDRO-[1,4]OXAZEPIN-3-YLAMINE OR 2,3,6,7-TETRAHYDRO-[1,4]OXAZEPIN-5-YLAMINE COMPOUNDS
- 专利标题（中）： -2,5,6,7-四氢 - [1,4]氧氮杂-3-基胺OR -2,3,6,7-四氢 - [1,4]氧氮杂-5-基胺化合物
-
申请号： EP11720065.9申请日： 2011-05-03
-
公开(公告)号： EP2566855A1公开(公告)日： 2013-03-13
- 发明人: BANNER, David , GUBA, Wolfgang , HILPERT, Hans , HUMM, Roland , MAUSER, Harald , MAYWEG, Alexander, V. , NARQUIZIAN, Robert , POWER, Eoin , ROGERS-EVANS, Mark , ROMBACH, Didier , WOLTERING, Thomas , WOSTL, Wolfgang
- 申请人： F.Hoffmann-La Roche AG , Siena Biotech S.p.a.
- 申请人地址： Grenzacherstrasse 124 4070 Basel CH
- 专利权人： F.Hoffmann-La Roche AG,Siena Biotech S.p.a.
- 当前专利权人： F.Hoffmann-La Roche AG,Siena Biotech S.p.a.
- 当前专利权人地址： Grenzacherstrasse 124 4070 Basel CH
- 代理机构： Müller-Afraz, Simona
- 优先权： EP10162340 20100507
- 国际公布： WO2011138293 20111110
- 主分类号： C07D267/10
- IPC分类号： C07D267/10 ; C07D413/12 ; C07D417/12 ; A61K31/553 ; A61P25/28
摘要：
This invention relates to compounds of the formula (I), wherein A, B and R
1 to R
7 are as described below, or to pharmaceutically acceptable salts thereof. These compounds are BACE1 and/or BACE2 inhibitors and can be used as 5 medicaments for the therapeutic and/or prophylactic treatment of diseases such as Alzheimer's disease, diabetes, particularly type 2 diabetes, and other metabolic disorders.
1 to R
7 are as described below, or to pharmaceutically acceptable salts thereof. These compounds are BACE1 and/or BACE2 inhibitors and can be used as 5 medicaments for the therapeutic and/or prophylactic treatment of diseases such as Alzheimer's disease, diabetes, particularly type 2 diabetes, and other metabolic disorders.
公开/授权文献
信息查询
